Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy.

[Saad, E. D.] Int Inst Drug Dev, Louvain, Belgium. [Buyse, M.] Int Inst Drug Dev, San Francisco, CA 94080 USA. [Buyse, M.] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat I BioSt, Hasselt, Belgium.

[1]  R. Doebele,et al.  Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  D. Sargent,et al.  Tumor-size-based endpoints as surrogates for overall survival in the ARCAD Advanced Colorectal Cancer Database. , 2017 .

[3]  W. Scheithauer,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. , 2016, The Lancet. Oncology.

[4]  G. Fontanini,et al.  FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. , 2015, The Lancet. Oncology.

[5]  U. Mansmann,et al.  Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). , 2015, European journal of cancer.

[6]  Sean Khozin,et al.  Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Buyse,et al.  VALIDATION OF SURROGATE ENDPOINTS IN ADVANCED SOLID TUMORS: SYSTEMATIC REVIEW OF STATISTICAL METHODS, RESULTS, AND IMPLICATIONS FOR POLICY MAKERS , 2013, International Journal of Technology Assessment in Health Care.

[8]  C. Tournigand,et al.  Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts. , 2014 .

[9]  D. Sargent,et al.  Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database. , 2014 .

[10]  I. Okamoto,et al.  Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  M. Buyse,et al.  Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Buyse,et al.  Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  D. Sargent,et al.  Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials , 2009, International Journal of Clinical Oncology.

[14]  Geert Molenberghs,et al.  Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.

[15]  G. Molenberghs,et al.  The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.

[16]  M Buyse,et al.  On the relationship between response to treatment and survival time. , 1996, Statistics in medicine.